Health Condition 1: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: Biosulin: 100IU/ml
Daily two to three times as advised by the physician
Subcutaneous administration for 6 months
Control Intervention1: Nil: Nil
Sponsors
M J Biopharm Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients who are willing to provide written, signed and dated informed consent (IEC/IRB approved) to participate in the study before initiating any study related procedures 2. Type II diabetic male or female adult patients, within 18 to 65 years of age(Inclusive) 3. Patients who are willing to comply with visit schedule and all aspects of the protocol requirements 4. Adult patients with type II diabetes mellitus who require Premix Human Insulin Biphasic 30/70 for the control of hyperglycemia according to the clinical judgment of the physician.. 5. Patients with glycosylated/glycated hemoglobin (HbA1c) level � 11 % at screening 6. Ability to self-inject insulin and perform self-monitoring of blood glucose (SMBG) measurements. Patients whose injection is being administered by caregiver/family member (only in the case wherein the patient has fear to self-inject or does not prefer to self-inject) will be enrolled
Exclusion criteria
Exclusion criteria: 1.History of Type I Diabetes mellitus or secondary diabetes mellitus or diabetes insipidus 2. Type 2 diabetic patients with metabolic complication such as diabetic ketoacidosis within 6 months of baseline visit 3. Patients who have used any other investigational agent in the past 3 months 4. Patients having mental incapacity, unwillingness or language barriers hindering adequate understanding or cooperation 5. Patients with history or evidence of hypersensitivity to the active substance (insulin) or to any of the excipients as mentioned in the local prescribing information 6. Women who are pregnant or nursing mothers. Women of childbearing potential not willing to use acceptable method of contraception 7. Any disorder which in the opinion of the treating physician might jeopardize subjectââ?¬•s safety or compliance with the protocol 8. Patient who has received/receiving insulin of animal origin 9. Patient with history or evidence of recurrent severe hypoglycemia within 6 months at baseline visit 10. Patients with use of insulin pump within 6 months at baseline visit 11. Patientââ?¬•s having the any of the following laboratory results at screening a. BUN > 30 mg/dL b. ALT/AST levels ââ?°Â¥ 2.5 X ULN of the normal laboratory range c. Serum creatinine level >2.0 mg/dL 12. Patients with known history of positive serology for hepatitis B virus (HBV) or hepatitis C (HCV) or human immunodeficiency virus (HIV) infections 13. Patients receiving glucagon-like peptide 1 mimetics (GLP-1) 14. Patients receiving treatment with thiazolidinedione (TZD) within the last 3 months at baseline visit 15. Patients with body mass index (BMI) 16. Patients who have undergone pancreatectomy or pancreas islet transplant or renal transplant 17. Patients receiving or have received within the last year any immunomodulation medications that would possibly modify antibody generation either at the enrollment or during the course of the study 18. Patients who have received/receiving ( >14 consecutive days) glucocorticoids within 4 weeks prior to baseline visit 19. Patients with history or evidence of diabetic complications (diabetic retinopathy, diabetic neuropathy, or diabetic nephropathy), other complications related to T2DM other than those mentioned, or cardiac disorders, etc. which in the opinion of the investigator signifies patientsââ?¬• ineligibility for the trial 20. Patients with alcohol or drug abuse or any other medical or surgical condition, including lifestyle (e.g. shift workers, irregularity with meal times, etc.) that in the opinion of investigator can interfere with the study protocol or affect patientââ?¬•s safety in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Percentage of patients reporting adverse events 2.Percentage of patients reporting serious adverse events 3.Insulin antibody changes Timepoint: From baseline to week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Improvement in HbA1c levels 2.Improvement in fasting blood glucose 3.Reduction in postprandial blood glucoseTimepoint: from baseline to week 24 | — |
Countries
India
Contacts
Public ContactArchana Gaikwad
Abiogenesis Clinpharm Private Limited
Outcome results
None listed